SYDNEY, Australia, Nov. 18 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS, Nasdaq: PXSL) today announced it had raised $11.7 million from its Share Purchase Plan which closed on 9 November 2007. Shareholders of the company were given the opportunity to purchase up to $5,000 worth of shares each at the $3.90 price paid by institutional investors in the recent placement.
A total of 2,496 shareholders participated in the plan under which the company will issue approximately 3 million new shares and receive cash of approximately $11.7 million.
Dr Alan Robertson, Chief Executive Officer of Pharmaxis said, "We are very encouraged with the level of support from our shareholders. Approximately half participated in the plan, and the average investment was over $4,600."
Shares will be issued today, 16th November 2007, and are expected to be listed on the Australian Securities Exchange on 19 November 2007. Holding statements will be posted on or about 19 November 2007.
Pharmaxis (ACN 082 811 630) is a pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory and immune disorders. Its development pipeline of products include, Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD) and PXS64 for the treatment of multiple sclerosis.
Founded in 1998, Pharmaxis is listed on the Australian Stock Exchange (symbol PXS), and on NASDAQ Global Market (symbol PXSL). The company is headquartered in Sydney at its TGA-approved manufacturing facilities. For more information about Pharmaxis, go to http://www.pharmaxis.com.au or contact Jane Sugden, Investor Relations +61 2 9454 7230.
The statements contained in this media release that are not purely
historical are forward-looking statement
|SOURCE Pharmaxis Ltd|
Copyright©2007 PR Newswire.
All rights reserved